Literature DB >> 22885422

High frequency of calcinosis in juvenile dermatomyositis: a risk factor study.

Gleice Clemente1, Daniela Gerent Petry Piotto, Cássia Barbosa, Octávio Augusto Peracchi, Claudio Arnaldo Len, Maria Odete Esteves Hilário, Maria Teresa R A Terreri.   

Abstract

OBJECTIVE: To assess the frequency of calcinosis in patients with juvenile dermatomyositis, and the possible risk factors for that manifestation.
METHODS: Medical record review of 34 patients, with an emphasis on the following characteristics: demographic, clinical and laboratory data; type of treatment; adherence to treatment; disease course (monocyclic, chronic and polycyclic); and disease severity. Patients were divided into two groups as follows: those who developed calcinosis (up to the sixth month of follow-up and after six months of follow-up) and those who did not develop calcinosis. Twenty-seven patients underwent two nailfold capillaroscopies (NFC), which were considered altered when the scleroderma pattern was found.
RESULTS: The mean age of symptom onset of the 34 patients was 6.5 years, the time until diagnosis was 1.2 years, and 70% were females. Half of the patients had a monocyclic disease course, and only 14.7% had severe vasculitis. Almost 90% of the patients undergoing NFC showed a change on the first assessment, 74% showed a change on the second assessment, and the mean interval between both assessments was 1.6 year. Calcinosis was evidenced in 16 (47.1%) patients. No association was observed between the variables analyzed and the development of calcinosis.
CONCLUSION: No risk factors for calcinosis were identified in this study, although that complication was found in half of the patients with juvenile dermatomyositis studied.

Entities:  

Mesh:

Year:  2012        PMID: 22885422

Source DB:  PubMed          Journal:  Rev Bras Reumatol        ISSN: 0482-5004


  9 in total

Review 1.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

2.  Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.

Authors:  Antonia Valenzuela; Lorinda Chung; Livia Casciola-Rosen; David Fiorentino
Journal:  JAMA Dermatol       Date:  2014-07       Impact factor: 10.282

3.  Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis.

Authors:  Slavica R Pavlov-Dolijanovic; Nada Z Vujasinovic Stupar; Nikola Gavrilov; Srdjan Seric
Journal:  Rheumatol Int       Date:  2014-05-01       Impact factor: 2.631

4.  Long-term outcomes in Juvenile Myositis patients.

Authors:  Vladislav Tsaltskan; Annette Aldous; Sam Serafi; Anna Yakovleva; Heidi Sami; Gulnara Mamyrova; Ira N Targoff; Adam Schiffenbauer; Frederick W Miller; Samuel J Simmens; Rodolfo Curiel; Olcay Y Jones; Lisa G Rider
Journal:  Semin Arthritis Rheum       Date:  2019-06-28       Impact factor: 5.532

5.  Radiographic patterns of soft tissue calcinosis in juvenile dermatomyositis and its clinical implications.

Authors:  Shantiranjan Sanyal; Swapndeep Singh Atwal; Debopriyo Mondal; Umesh Chandra Garga
Journal:  J Clin Diagn Res       Date:  2014-12-05

Review 6.  Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis.

Authors:  Melody P Chung; Carrie Richardson; David Kirakossian; Amir B Orandi; Lesley A Saketkoo; Lisa G Rider; Adam Schiffenbauer; Carlos A von Mühlen; Lorinda Chung
Journal:  Autoimmun Rev       Date:  2020-03-28       Impact factor: 9.754

7.  Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA).

Authors:  A B Orandi; K W Baszis; V R Dharnidharka; A M Huber; M F Hoeltzel
Journal:  Pediatr Rheumatol Online J       Date:  2017-09-21       Impact factor: 3.054

8.  Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series.

Authors:  Natasa Toplak; Pallavi Pimpale Chavan; Silvia Rosina; Tomas Dallos; Oz Rotem Semo; Cassyanne L Aguiar; Raju Khubchandani; Angelo Ravelli; Anjali Patwardhan
Journal:  Front Pediatr       Date:  2022-02-23       Impact factor: 3.418

9.  Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.

Authors:  Amir B Orandi; Vikas R Dharnidharka; Noor Al-Hammadi; Kevin W Baszis
Journal:  Pediatr Rheumatol Online J       Date:  2018-12-29       Impact factor: 3.054

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.